• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Primary therapy with SLT has potential for durable efficacy

Article

Boston-Selective laser trabeculoplasty (SLT) is safe and effective as initial treatment for primary open-angle glaucoma (POAG) or pseudoexfoliation (PXF) glaucoma, and it can maintain IOP control in some eyes for 30 months or longer, said Mark A. Latina, MD.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
Related Content
Blog: Managing patients with MGD and Demodex blepharitis

Blog: Managing patients with MGD and Demodex blepharitis

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
More than meets the eye: Researchers uncover the microbial secrets of dry eye

More than meets the eye: Researchers uncover the microbial secrets of dry eye

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
Kiora Pharmaceuticals receives grant to fund novel clinical trial endpoints for inherited retinal diseases

Kiora Pharmaceuticals receives grant to fund novel clinical trial endpoints for inherited retinal diseases

Article
Opthea highlights latest phase 3 trials for sozinibercept

Opthea highlights latest phase 3 trials for sozinibercept

Article
© 2024 MJH Life Sciences

All rights reserved.